Cardiovascular Function in Acute Leukemia
NCT03760237 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84
Last updated 2024-10-10
Summary
An observational, prospective study to describe the rates and predictors of cardiovascular events in patients with acute leukemia.
Conditions
- Leukemia, Myeloid, Acute
- Leukemia, Lymphoid, Acute
- Cardiotoxicity
Interventions
- OTHER
-
observation only
No intervention, observational study only
Sponsors & Collaborators
-
Abramson Cancer Center at Penn Medicine
lead OTHER
Principal Investigators
-
Marielle Scherrer-Crosbie, MD, PhD · University of Pennsylvania
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-10
- Primary Completion
- 2024-05-06
- Completion
- 2024-05-06
Countries
- United States
Study Locations
More Related Trials
-
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
NCT03680677 ·Status: RECRUITING
-
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias
NCT02759822 ·Status: UNKNOWN
-
Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
NCT03603795 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.
NCT03350152 ·Status: COMPLETED
-
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
NCT00023777 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia
NCT02345915 ·Status: UNKNOWN ·Phase: NA
-
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
NCT03030612 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assessing Refractoriness and Infectious Survival Events in AML
NCT06709235 ·Status: COMPLETED
-
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00795002 ·Status: COMPLETED ·Phase: PHASE2
-
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
NCT03597321 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00016302 ·Status: COMPLETED ·Phase: NA
-
Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML
NCT03023384 ·Status: UNKNOWN
-
Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .
NCT07343687 ·Status: NOT_YET_RECRUITING
-
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
NCT03610438 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
NCT00003758 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
NCT06362031 ·Status: WITHDRAWN
-
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
NCT02287233 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
NCT01169363 ·Status: COMPLETED
-
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00003700 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
NCT00015951 ·Status: COMPLETED ·Phase: PHASE2
-
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
NCT00071006 ·Status: COMPLETED ·Phase: PHASE2
-
MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
NCT02067143 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma
NCT00195871 ·Status: UNKNOWN ·Phase: PHASE2
-
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
NCT03256071 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
NCT06906380 ·Status: NOT_YET_RECRUITING